Unleash Long-Term Gains with Top Momentum Stock EXEL
Unlocking the Secrets of the Stock Market: How to Invest with Confidence
For many investors, navigating the complexities of the stock market can be a daunting task. Whether you’re a seasoned pro or just starting out, having a solid understanding of how to make informed investment decisions is crucial for achieving success in this arena. One way to gain an edge is by utilizing the Zacks Style Scores, a valuable tool that helps identify winning stocks based on your preferred investing style.
The Zacks Style Scores are indicators that rate stocks according to three widely-followed investing types: value, growth, and momentum. For momentum investors, upward or downward trends in a stock’s price or earnings outlook take precedence. This group of investors will want to focus on the Momentum Style Score, which can pinpoint good times to build a position in a stock by considering factors like one-week price change and the monthly percentage change in earnings estimates.
Momentum Investing: A Key Focus Area
When it comes to momentum investing, identifying stocks that are exhibiting strong upward or downward trends is essential. This type of investor relies heavily on the idea that past performance can be indicative of future success. The Momentum Style Score takes into account various metrics, including:
- One-week price change
- Monthly percentage change in earnings estimates
By examining these factors, momentum investors can gain valuable insights into a stock’s potential for growth or decline.
Exelixis: A Prime Example
One company that stands out as a prime example of momentum investing is Exelixis, Inc. (EXEL). Based in Alameda, CA, Exelixis is an oncology-focused biotechnology company dedicated to the discovery, development, and commercialization of new drugs for treating difficult-to-treat cancers.
- EXEL holds a Zacks Rank #2 (Buy) and boasts an A score on the Momentum Style Score
- The stock has experienced significant growth over the past year, with a 96.3% increase in value
- An average of 3,878,287.25 shares were traded over the last 20 trading sessions
Investors should take note of Exelixis’s impressive earnings metrics, including:
- Nine analysts revised their earnings estimate higher in the last 60 days for EXEL
- The Zacks Consensus Estimate has increased $0.26 to $2.57 per share for fiscal 2025
- EXEL boasts an average earnings surprise of 48.6%
Why Exelixis Stands Out
Exelixis’s solid Zacks Ranks, notable earnings metrics, and impressive Momentum and VGM Style Scores make it a compelling choice for investors seeking to capitalize on momentum opportunities. With its clinically differentiated pipeline of small molecules, antibody-drug conjugates (ADCs), and other biotherapeutics, Exelixis is well-positioned to target an expanding range of tumor types and indications.
Conclusion
In conclusion, utilizing the Zacks Style Scores can be a valuable tool for investors seeking to make informed decisions in the stock market. By focusing on momentum investing and identifying stocks that are exhibiting strong upward or downward trends, investors can gain a competitive edge. Exelixis is an exemplary case of a company that has demonstrated impressive growth potential, making it an attractive choice for momentum investors.
